RAS-acting Agents Market

RAS-acting Agents Market (Drug Class: ACE Inhibitors, Angiotensin II Receptor Blockers [ARBs], Renin Inhibitors, Aldosterone Antagonists, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global RAS-acting Agents Market Outlook 2031

  • The global industry was valued at US$ 9.7 Bn in 2022
  • It is projected to grow at a CAGR of 4.2% from 2023 to 2031 and reach more than US$ 13.4 Bn by the end of 2031

Analysts’ Viewpoint

Continuous research & development, increase in prevalence of cardiovascular diseases (CVDs), and development of new combination therapies and precision medicine approaches are driving the global RAS-acting agents market. Increase in investment by pharmaceutical companies in research & development, particularly in the area of CVDs, are expected to propel market expansion.

Combination therapies that target multiple aspects of the renin-angiotensin system (RAS) are gaining popularity, as these can be more effective than single-agent therapies. Manufacturers primarily focus on the development of new combination therapies in order to increase market share and presence.

Ras Acting Agents Market

RAS-acting Agents Market Introduction

The renin-angiotensin system (RAS) is a complex hormonal system that helps regulate blood pressure and fluid balance in the body. RAS-acting agents/drugs target different components of this system and are used to treat various cardiovascular and renal disorders. The action of ACE enzymes, which convert angiotensin I to angiotensin II, is blocked by angiotensin-converting enzyme (ACE) inhibitors. Angiotensin II is a potent vasoconstrictor that can raise blood pressure. ACE inhibitors, such as lisinopril, enalapril, and captopril, lower blood pressure by reducing the production of angiotensin II.

RAS-acting agents significantly impact cardiovascular and renal health and are used to manage various conditions related to high blood pressure and heart failure. However, these could also cause side effects such as hypotension, cough, and hyperkalemia. Hence, they should be used under the guidance of a healthcare professional.

Increase in the Prevalence of CVD Globally

The increase in the prevalence of CVDs is one of the key drivers of global business. According to the World Health Organization (WHO), CVD is the leading cause of death worldwide, accounting for nearly 17.9 million deaths each year.

RAS-acting agents are commonly used to treat hypertension and heart failure, both of which are major risk factors for CVDs. An increase in the incidence of these conditions drives demand for RAS-acting agents. Additionally, ongoing research into the potential use of RAS-acting agents for other conditions, such as kidney disease, is expected to augment the RAS-acting agents market forecast.

The surge in the availability of generic versions of these drugs is propelling the market. This is making treatment more affordable for patients and expanding their access to health care. However, the market faces challenges such as competition from alternative treatments and potential side effects associated with RAS-acting agents.

Continuous Research and Development

The RAS is a complex hormonal system, which plays a critical role in regulating blood pressure and fluid balance in the body. Ongoing RAS-acting agents market research into the many components of the system and its potential therapeutic targets leads to market expansion.

New drugs that target different components of RAS are being developed and tested, including agents that target renin, ACE, angiotensin II receptors, and other key proteins in the system. Additionally, continuous research into the use of RAS-acting agents for the treatment of other conditions, such as kidney disease and pulmonary hypertension, augment the market.

A rise in interest in the development of combination therapies, which target multiple components of RAS simultaneously, with the goal of achieving more effective blood pressure control and improved outcomes, also propels the market. For example, combination therapies that include both an ACE inhibitor and an angiotensin II receptor blocker (ARB) have been shown to be effective in some patients with hypertension. These factors are fueling global RAS-acting agents industry growth.

Well-established Safety and Efficacy Profile of ACE Inhibitors

In terms of drug class, the ACE inhibitors segment accounted for the leading global RAS-acting agents market share in 2022. ACE inhibitors are widely prescribed for the treatment of hypertension and heart failure. These drugs work by blocking the action of ACE, an enzyme that converts angiotensin I to angiotensin II and is a potent vasoconstrictor, which can raise blood pressure.

ACE inhibitors are recommended as first-line therapy in several major clinical guidelines for the treatment of hypertension and heart failure, further contributing to their widespread usage and market dominance. Lisinopril, enalapril, and ramipril.

ACE inhibitors have been used for several decades, and are considered a standard of care for several patients with hypertension and heart failure. These have a well-established safety and efficacy profile and are available in both generic and branded formulations.

Availability of New & Improved RAS-acting Agents Driving Hypertension Segment

Based on indication, the hypertension segment dominated the global market in 2022. Hypertension, or high blood pressure, is a common condition that affects a large number of people across the world and is a major risk factor for a range of CVDs, including stroke, heart attack, and heart failure.

RAS-acting agents, particularly ACE inhibitors and ARBs, are widely used for the treatment of hypertension. These drugs work by reducing the activity of RAS, thereby lowering blood pressure and reducing the risk of cardiovascular complications. Additionally, RAS-acting agents are often used in combination with other classes of antihypertensive drugs, such as diuretics or calcium channel blockers, to achieve optimal blood pressure control.

The hypertension indication segment is expected to continue to grow in the next few years owing to a surge in the prevalence of hypertension, the availability of new and improved RAS-acting agents, and an increase in focus on combination therapies for hypertension management.

Access to RAS-acting Agents, including Newer & More Specialized Drugs in Hospital Pharmacies

In terms of distribution channels, the hospital pharmacies segment accounted for a significant share of the global RAS-action agents market in 2022. Hospital pharmacies are an important distribution channel for RAS-acting agents, particularly for patients with hypertension, heart failure, and other CVDs who are hospitalized or receiving treatment in an inpatient setting.

Hospital pharmacies often have access to a range of RAS-acting agents, including newer and more specialized drugs that may not be available in retail pharmacies. This can be particularly important for patients with complex medical conditions who require tailored treatment regimens.

Hospital pharmacies are also often responsible for the administration of RAS-acting agents in a hospital or clinical setting, through intravenous infusion or injection. This can require specialized expertise and equipment, which may not be available in other types of pharmacies.

Regional Outlook

North America accounted for a major share of the global RAS-acting agents market in 2022. This can be attributed to the high prevalence of CVDs, such as hypertension and heart failure, in the region, the availability of advanced healthcare infrastructure and facilities, and the presence of several key market players.

North America also has a strong regulatory environment and well-established healthcare system, which can facilitate the development and commercialization of new RAS-acting agents. High levels of research & development activities are undertaken in the pharmaceutical industry in the region, which can lead to the discovery and development of new drugs targeting the RAS.

Analysis of Key Players

Product portfolio expansion and mergers & acquisitions are key strategies adopted by key manufacturers in the global RAS-acting agents market. Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, and Johnson & Johnson are the prominent players in the market.

Key Developments in the Global RAS-acting Agents Market

  • In November 2021, Boehringer Ingelheim announced the launch of a new fixed-dose combination product containing telmisartan and amlodipine besylate for the treatment of hypertension. The product, called Twynsta Duo, is now available in the U.S.
  • In October 2021, AstraZeneca and Amgen announced the results of phase 3 clinical trial of their RAS-acting agent, tezepelumab, in patients with severe asthma. The trial met its primary endpoint of reducing asthma exacerbations. The companies plan to seek regulatory approval for the drug.
  • In August 2021, Pfizer announced that its RAS-acting agent, tafamidis, received approval from the European Commission for the treatment of transthyretin amyloid cardiomyopathy, a rare and life-threatening condition that affects the heart.

The RAS-acting agents market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent market developments.

Global RAS-acting Agents Market Snapshot

Attribute

Detail

Size in 2022

US$ 9.7 Bn

Forecast (Value) in 2031

More than US$ 13.4 Bn

Growth Rate (CAGR)

4.2%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • ACE Inhibitors
    • Angiotensin II Receptor Blockers (ARBs)
    • Renin Inhibitors
    • Aldosterone Antagonists
    • Others (diuretics)
  • Indication
    • Hypertension
    • Heart Failure
    • Chronic Kidney Disease
    • Diabetic Nephropathy
    • Coronary Artery Disease
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Novartis AG
  • Pfizer, Inc.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global RAS-acting agents market in 2022?

The global industry was valued at US$ 9.7 Bn in 2022.

How big the industry will be in 2031?

It is projected to reach more than US$ 13.4 Bn by 2031.

What CAGR the business is estimated to register during the forecast period?

The business is anticipated to grow at a CAGR of 4.2% from 2023 to 2031.

Which are the prominent driving factors?

Increase in prevalence of CVDs globally and continuous research and development are the prominent players in the market.

Which is likely to be a key region during the forecast period?

North America is estimated to be a prominent region during the forecast period.

Who are the prominent players in the global RAS-acting agents industry?

Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, and Johnson & Johnson are the prominent players in the market.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global RAS-acting Agents Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Technological Advancements

    5.2. Disease Prevalence & Incidence Rate Globally With Key Countries

    5.3. Key Industry Events

    5.4. COVID-19 Impact Analysis

6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. ACE inhibitors

        6.3.2. Angiotensin II Receptor Blockers (ARBs)

        6.3.3. Renin Inhibitors

        6.3.4. Aldosterone Antagonists

        6.3.5. Others (diuretics)

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global RAS-acting Agents Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Indication, 2017–2031

        7.3.1. Hypertension

        7.3.2. Heart Failure

        7.3.3. Chronic Kidney Disease

        7.3.4. Diabetic Nephropathy

        7.3.5. Coronary Artery Disease

    7.4. Market Attractiveness Analysis, by Indication

8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global RAS-acting Agents Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017–2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America RAS-acting Agents Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. ACE inhibitors

        10.2.2. Angiotensin II Receptor Blockers (ARBs)

        10.2.3. Renin Inhibitors

        10.2.4. Aldosterone Antagonists

        10.2.5. Others (diuretics)

    10.3. Market Value Forecast, by Indication, 2017–2031

        10.3.1. Hypertension

        10.3.2. Heart Failure

        10.3.3. Chronic Kidney Disease

        10.3.4. Diabetic Nephropathy

        10.3.5. Coronary Artery Disease

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Indication

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe RAS-acting Agents Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. ACE inhibitors

        11.2.2. Angiotensin II Receptor Blockers (ARBs)

        11.2.3. Renin Inhibitors

        11.2.4. Aldosterone Antagonists

        11.2.5. Others (diuretics)

    11.3. Market Value Forecast, by Indication, 2017–2031

        11.3.1. Hypertension

        11.3.2. Heart Failure

        11.3.3. Chronic Kidney Disease

        11.3.4. Diabetic Nephropathy

        11.3.5. Coronary Artery Disease

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Indication

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific RAS-acting Agents Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. ACE inhibitors

        12.2.2. Angiotensin II Receptor Blockers (ARBs)

        12.2.3. Renin Inhibitors

        12.2.4. Aldosterone Antagonists

        12.2.5. Others (diuretics)

    12.3. Market Value Forecast, by Indication, 2017–2031

        12.3.1. Hypertension

        12.3.2. Heart Failure

        12.3.3. Chronic Kidney Disease

        12.3.4. Diabetic Nephropathy

        12.3.5. Coronary Artery Disease

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Indication

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. ACE inhibitors

        13.2.2. Angiotensin II Receptor Blockers (ARBs)

        13.2.3. Renin Inhibitors

        13.2.4. Aldosterone Antagonists

        13.2.5. Others (diuretics)

    13.3. Market Value Forecast, by Indication, 2017–2031

        13.3.1. Hypertension

        13.3.2. Heart Failure

        13.3.3. Chronic Kidney Disease

        13.3.4. Diabetic Nephropathy

        13.3.5. Coronary Artery Disease

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of LATAM

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Indication

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. ACE inhibitors

        14.2.2. Angiotensin II Receptor Blockers (ARBs)

        14.2.3. Renin Inhibitors

        14.2.4. Aldosterone Antagonists

        14.2.5. Others (diuretics)

    14.3. Market Value Forecast, by Indication, 2017–2031

        14.3.1. Hypertension

        14.3.2. Heart Failure

        14.3.3. Chronic Kidney Disease

        14.3.4. Diabetic Nephropathy

        14.3.5. Coronary Artery Disease

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Indication

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company (2022)

    15.3. Company Profiles

        15.3.1. Novartis AG

            15.3.1.1. Company Overview

            15.3.1.2. Drug Class Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Pfizer, Inc.

            15.3.2.1. Company Overview

            15.3.2.2. Drug Class Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. AstraZeneca plc

            15.3.3.1. Company Overview

            15.3.3.2. Drug Class Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Merck & Co., Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Drug Class Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Sanofi S.A.

            15.3.5.1. Company Overview

            15.3.5.2. Drug Class Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Bristol-Myers Squibb Company

            15.3.6.1. Company Overview

            15.3.6.2. Drug Class Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. Daiichi Sankyo Company, Limited

            15.3.7.1. Company Overview

            15.3.7.2. Drug Class Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Takeda Pharmaceutical Company Limited

            15.3.8.1. Company Overview

            15.3.8.2. Drug Class Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Boehringer Ingelheim GmbH

            15.3.9.1. Company Overview

            15.3.9.2. Drug Class Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Johnson & Johnson

            15.3.10.1. Company Overview

            15.3.10.2. Drug Class Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

List of Tables

Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global RAS-acting Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global RAS-acting Agents Market Revenue (US$ Mn), by Drug Class, 2022

Figure 03: Global RAS-acting Agents Market Value Share, by Drug Class, 2022

Figure 04: Global RAS-acting Agents Market Revenue (US$ Mn), by Indication, 2022

Figure 05: Global RAS-acting Agents Market Value Share, by Indication, 2022

Figure 06: Global RAS-acting Agents Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global RAS-acting Agents Market Value Share, by Distribution Channel, 2022

Figure 08: Global RAS-acting Agents Market Value Share, by Region, 2022

Figure 09: Global RAS-acting Agents Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 11: Global RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 12: Global RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 13: Global RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031

Figure 14: Global RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 15: Global RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 16: Global RAS-acting Agents Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global RAS-acting Agents Market Attractiveness Analysis, by Region, 2023-2031

Figure 18: North America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America RAS-acting Agents Market Attractiveness Analysis, by Country, 2017–2031

Figure 20: North America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: North America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 22: North America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 23: North America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 24: North America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 25: North America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 26: North America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 27: Europe RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 29: Europe RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: Europe RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 32: Europe RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 33: Europe RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 34: Europe RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 35: Europe RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 38: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 40: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 41: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 42: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 44: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 47: Latin America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 49: Latin America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 50: Latin America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 51: Latin America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 52: Latin America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 53: Latin America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 56: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 58: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 59: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 60: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 61: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 62: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved